Sysmex Enters into R&D and Licensing Agreement with Merck Millipore
News Mar 18, 2014
Sysmex Corporation has entered into a clinical research, joint development and licensing agreement with Merck Millipore involving Merck Millipore imaging flow cytometry technology.
If successful, Sysmex and Merck Millipore will collaborate on developing the imaging flow technology platform for the future commercialization in hematology.
Sysmex has developed various products to analyze cells within the blood, using flow cytometry (FCM) as a platform that can be easily deployed in a clinical setting.
This agreement involves the imaging flow cytometry technology developed by Amnis which was acquired by Merck Millipore in 2011. It is a unique, highly differentiated technology platform that combines the power of flow cytometry with rapid capture of high volume images of cell morphology, fluorescent imaging, and automated digital image analysis. The clinical study will assess the use of imaging flow cytometry technology as a platform for diagnosing hematologic disorders such as leukemia.
Once clinical research is complete, the parties intend to develop more powerful diagnostic tools that will generate image data of molecular (protein) expression status, as well as the identification of abnormal cells in the blood. Sysmex aims to promote the creation of new diagnostic technologies that will enable the realization of personalized medicine and contribute to the advancement of healthcare by meeting increasingly diverse and sophisticated testing needs.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.